CClinicalTrials.gg
RecruitingNCT03224091PROLEDUpdated Apr 7, 2022

PROspective Longitudinal All-comer Inclusion Study in Eating Disorders

An observational study in Anorexia Nervosa, Bulimia Nervosa and Binge-Eating Disorder, sponsored by Mental Health Services in the Capital Region, Denmark. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-07.

Sponsored by Mental Health Services in the Capital Region, Denmark · Observational

From the registry’s dates

  • Started Jan 2016; still recruiting 10 years 8 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The PROLED study is a prospective and longitudinal study of patients with Eating Disorders. Annual interviews and collection of biological samples are done, as well as during changes in disease course e.g. during hospitalization. Included are qualitative interviews, psychometric tests, questionnaires which are used to collect data on psychopathology. There is also collection of blood, urine and faeces.

Read the detailed description

The objective is to increase the understanding of the psychopathology and pathophysiology of Eating Disorders.

More specifically, the aim is to identify biomarkers that relate to prognosis, disease course and response to treatment as usual of Eating Disorders, and, to improve the understanding of the pathophysiology of Eating disorders in order to identify novel molecular targets for treatment.

Rationale The etiology of Eating Disorders (ED's) is unknown. Previous studies have identified genes that link Anorexia Nervosa to other psychiatric (e.g. schizophrenia) and somatic disorders (e.e. diabetes). Association studies have also suggested genetic causes underlying Bulimia Nervosa and Binge Eating Disorders. The PROLED study aims to improve the understanding of both the psychopathology and pathophysiology of Eating Disorders. No experimental drug will be used in this study.

There is a great need for an increased biological understanding of ED's in view of the prevalence, the costs, the severity and high mortality rates, and the lack of efficient treatments. The PROLED study aims to answer questions related to these unmet medical needs.

The study design is prospective and longitudinal. Qualitative interviews, psychometric tests, questionnaires are used to collect data on psychopathology. There is also collection of blood, urine and faeces.

02

Conditions studied

  • Anorexia Nervosa
  • Bulimia Nervosa
  • Binge-Eating Disorder
  • Eating Disorder NOS

Keywords

  • Eating disorders
  • psychopathology
  • pathophysiology
  • prospective
  • longitudinal
03

In context

Anorexia

411 studies on the registry are indexed under Anorexia; 67 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 65 across 104 observational studies indexed under Anorexia.

Browse Anorexia studies →

Lead sponsor

Mental Health Services in the Capital Region, Denmark is the lead sponsor of 51 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Patients at Psychiatric Center Ballerup with Eating Disorders

Inclusion criteria

  • Eating Disorder (ICD-10)

Exclusion criteria

Exclusion Criteria:

  • Forced care/non-voluntary
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients at Psychiatric Center Ballerup
  • Healthy Controls
  • Healthy Controls recovered from an eating disorder
06

What researchers measure

Primary outcomes

  1. GAF-F total score

    Change in Global level of functioning will be assessed using the GAF-F score for the whole population of treated individuals

    Time frame: through study completion, an average of 1 year

  2. BMI change over time

    Change in Body Mass Index (BMI) will be assess in the whole population of Anorexia Nervosa patients and compared to other diagnoses and Healthy controls, change over time

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. MDI

    Change in Major Depressive Inventory will be used to assess depressiveness, assessed for all patients with one diagnosis and compared to other diagnoses and healthy controls; change over time

    Time frame: through study completion, an average of 1 year

  2. cytokines in plasma

    Change in inflammatory parameters in blood as a measure of inflammation status

    Time frame: through study completion, an average of 1 year

  3. Biomarkers in blood

    Change in biomarker parameters in blood as a measure of change in biological parameters

    Time frame: through study completion, an average of 1 year

  4. Total score on CogTrac

    Change in cognitive performance

    Time frame: through study completion, an average of 1 year

  5. Change in EDI

    Change in Eating disorder related behaviour and symptoms

    Time frame: through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
  • Mental Health Center
    Ballerup, Capitol Region 2750, Denmark
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03224091
Lead sponsor
Mental Health Services in the Capital Region, Denmark
Collaborators
University of Southern Denmark, University of Copenhagen, Statens Serum Institut
Responsible party
Jan Magnus Sjögren (Research Associate Professor, Sr Consultant Psychiatrist, Mental Health Services in the Capital Region, Denmark) — Principal investigator
First posted
Jul 21, 2017
Start date
Jan 25, 2016
Primary completion
Apr 1, 2030 (estimated)
Completion
Apr 1, 2030 (estimated)
Last update
Apr 7, 2022

Study contacts

Magnus JC Sjögren, MD, PhD
Contact
jan.magnus.sjoegren@regionh.dk
+4538645157
Louise Behrend_Rasmussen, MD,PhD
study chair · Mental Health Center Ballerup

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion